MSS
DXCM icon

Mitchell Sinkler & Starr’s DexCom DXCM Stock Holding History

Mitchell Sinkler & Starr’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,360
Closed -$206K – 146
2025
Q2 		$206K Buy
+2,360
New +$185K 0.1% 141
2025
Q1 		– Sell
-2,838
Closed -$221K – 157
2024
Q4 		$221K Buy
+2,838
New +$210K 0.06% 152
2024
Q3 		– Sell
-2,838
Closed -$314K – 190
2024
Q2 		$314K Buy
2,838
+1,200
+73% +$152K 0.08% 120
2024
Q1 		$227K Sell
1,638
-6,872
-81% -$864K 0.06% 152
2023
Q4 		$1.06M Buy
8,510
+1,920
+29% +$196K 0.19% 93
2023
Q3 		$615K Buy
6,590
+3,780
+135% +$426K 0.19% 74
2023
Q2 		$361K Hold
2,810
– – 0.1% 112
2023
Q1 		$326K Buy
2,810
+272
+11% +$30.4K 0.1% 116
2022
Q4 		$287K Buy
+2,538
New +$279K 0.09% 121
2022
Q2 		– Sell
-1,708
Closed -$218K – 115
2022
Q1 		$218K Hold
1,708
– – 0.07% 117
2021
Q4 		$229K Hold
1,708
– – 0.07% 116
2021
Q3 		$234K Buy
+1,708
New +$215K 0.21% 98

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mitchell Sinkler & Starr's DXCM Position: Q3 2025 in Review

Mitchell Sinkler & Starr sold out of DexCom (DXCM) in Q3 2025, closing a stake of 2,360 shares — an estimated $206K sold.

Mitchell Sinkler & Starr first reported a position in DXCM in Q3 2021 and held it in 12 quarters. The position peaked at $1.06M in Q4 2023. 910 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • Mitchell Sinkler & Starr reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
  • Mitchell Sinkler & Starr sold 2,360 DexCom shares in Q3 2025, an estimated $206K.
  • Mitchell Sinkler & Starr first reported a position in DexCom in Q3 2021 and held it in 12 quarters.
  • Mitchell Sinkler & Starr's DexCom position peaked at $1.06M in Q4 2023.
  • 910 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Mitchell Sinkler & Starr's 13F filing for Q3 2025, filed 4 Nov 2025.